COMBINATION COMPRISING AN ALPHA-2-DELTA LIGAND AND SSRI AND(OR) SNRI FOR TREATMENT OF DEPRESSION AND ANXIETY DISORDERS

A method is provided of treating depression in mammals, including a human, as well as depression and a concomitant disease, disorder or condition exemplified by, but not limited to, anxiety, sleep disorder and post-traumatic stress disorder. The method comprises administering to the mammal in effective amount a combination of active ingredients comprising a) an alpha-2delta (A2D) ligand or a prodrug thereof, or a pharmaceutically acceptable salt of said 2D ligand or said prodrug and, active agents selected from; (b) a selective serotonin re-uptake inhibitor (SSRI) or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) a selective noradrenaline re- uptake inhibitor (SNRI) or a prodrug thereof or a pharmaceutically acceptable salt of said NRI or said prodrug and mixtures of (b) and (c). A pharmaceutical composition comprising a therapeutically effective amount (a) an A2D ligand or a pro g thereof, or a pharmaceutically acceptable salt of said A2D ligand or said prodrug and active agents selected from; (b) an SSRI or a prodrug thereof or a pharmaceutically acceptable salt of said SSRI or said prodrug, (c) an SNR or a prodrug thereof or a pharmaceutically acceptable salt of said SNRI or said is prodrug and mixtures of (b) and (c) is also provided. Preferred active ingredients for the treatment and the pharmaceutical composition include pregabalin, gabapentin, sertraline and reboxetine.